NSI-189

Also known as: SNN-012

Evidence Tier Cmedium riskadvancedinvestigational

Investigational neurogenic small molecule often discussed in nootropic circles despite limited human data.

Overview

NSI-189 is not a peptide but an investigational neurogenic compound included here because users often compare it with cognitive peptide stacks. Early human work suggests tolerability and possible mood or hippocampal effects, but the evidence base is still small and not sufficient for strong consumer conclusions.

Research Details

Mechanism of Action

Putative neurogenic and synaptogenic signaling; exact mechanism remains incompletely characterized.

Study Dose Range

Early human studies used up to 40 mg daily by mouth.

Administration Routes

oral

Onset / Timeline

Any central effects would be expected over weeks rather than days.

Expected Effects

Possible mood and cognitive-support effects remain speculative outside limited early human studies.

Adverse Effects

Limited human safety base; mild insomnia or GI upset reported in small studies.

Contraindications

No clear formal contraindications; treat as an experimental CNS-active compound.

Interaction Notes

Avoid confident multi-nootropic stacking claims because mechanistic overlap and safety data are limited.

Related Goals

Cognitive & NeuroprotectionAnxiety & Mood

Known Interactions

caution with Cerebrolysin

Two experimental neurotrophic-style agents with little human combination data.

caution with Dihexa

Experimental nootropic stack with limited human data and unclear downside profile.

caution with Semax

Mechanistically interesting but human combination data are weak; conservative caution.

caution with Selank

CNS-active experimental pairing with uncertain interaction profile.

Available From

No vendors currently listed for this peptide.

Frequently Compared

Semax

ACTH fragment analogue with preclinical neurotrophic signaling and limited clinical stroke/cognition data.

Tier B-C

Selank

Tuftsin analogue peptide with anxiolytic/nootropic research and limited clinical GAD data.

Tier B-C

DSIP

Sleep-related peptide with human IV infusion studies showing sleep pressure effects. Mechanism uncertain.

Tier B

Oxytocin

Well-studied neuropeptide with extensive human research on social/emotional processing. Prescription product.

Tier A

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.